{"id":"jta-004","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Immune-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JTA-004 consists of expanded allogeneic mesenchymal stem cells that are administered to support bone healing and regeneration through paracrine signaling, immunomodulation, and direct differentiation into bone-forming cells. The therapy is designed to enhance the body's natural bone repair mechanisms in fracture healing and other bone defect applications.","oneSentence":"JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:38.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bone fractures (femoral shaft fractures)"},{"name":"Bone defects and non-union fractures"}]},"trialDetails":[{"nctId":"NCT04333160","phase":"PHASE3","title":"Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis","status":"COMPLETED","sponsor":"Bone Therapeutics S.A","startDate":"2020-03-10","conditions":"Symptomatic Osteoarthritis of the Knee","enrollment":746},{"nctId":"NCT02740231","phase":"PHASE2, PHASE3","title":"A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis","status":"COMPLETED","sponsor":"Bone Therapeutics S.A","startDate":"2016-02","conditions":"Knee Osteoarthritis","enrollment":173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JTA-004","genericName":"JTA-004","companyName":"Bone Therapeutics S.A","companyId":"bone-therapeutics-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair. Used for Acute bone fractures (femoral shaft fractures), Bone defects and non-union fractures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}